相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
66.7%
终止
1
33.3%
暂无批准数据
- Neurocrine Biosciences has agreed to acquire Soleno Therapeutics, a biopharmaceutical company developing novel therapeutics for rare diseases, in a $2.9 billion transaction. - The acquisition represents Neurocrine's strategic expansion into the rare disease therapeutic space, building on its existing portfolio of specialized treatments. - Soleno focuses on developing and commercializing innovative therapies specifically targeting rare disease populations with significant unmet medical needs. - This marks another major acquisition for Neurocrine following its 2023 purchase of Diurnal, demonstrating continued consolidation in the rare disease sector.
- Tempero Bio has raised $70 million in Series B financing to advance TMP-301, a novel mGluR5 negative allosteric modulator targeting the neurobiological basis of addiction, through Phase 2 clinical trials. - The company has already initiated a Phase 2 trial for alcohol use disorder and plans to begin cocaine use disorder studies within the next year, addressing conditions that affect millions of Americans with limited treatment options. - Industry veteran John Wagner, M.D., Ph.D., with over 20 years of drug development experience, will join Tempero Bio as Chief Medical Officer to oversee the clinical advancement of TMP-301.
- Verily's Immune Profiler platform has successfully identified novel GPCR targets for autoimmune diseases within six months of launching collaboration with Sosei Heptares. - The platform demonstrates remarkable capability to analyze over 8 million immune measures across 24 immune cell subsets, accelerating the identification of therapeutic targets. - The partnership aims to advance identified targets into validation and lead selection phases, potentially revolutionizing treatment options for immune-mediated diseases.
- Boehringer Ingelheim licenses GPR52 agonists from Sosei Heptares for €755m, targeting a range of schizophrenia symptoms including positive, negative, and cognitive dysfunction. - The collaboration with Autifony Therapeutics focuses on Kv3.1/3.2 positive modulators, with Boehringer funding R&D and holding an option to purchase AUT00206, currently in Phase 1b. - These deals complement Boehringer's existing schizophrenia pipeline, including iclepertin (GlyT1 inhibitor) in Phase 3 and a digital therapeutic (DTx) in late-stage testing.
- Genentech has secured partnerships with Convelo Therapeutics, Sosei Heptares, and Skyhawk Therapeutics to enhance its small-molecule drug discovery capabilities across multiple therapeutic areas. - The Sosei Heptares collaboration, valued at up to $1 billion, focuses on GPCR drug targets, while Convelo's partnership aims to develop remyelination therapies for multiple sclerosis. - Skyhawk Therapeutics partnership will explore RNA-splicing modulation for cancer and neurodegenerative diseases, expanding Genentech's reach into novel therapeutic approaches.
